← FDA DRUG APPROVALS

FDA ANDA · ANDA203711

ONDANSETRON

Sponsor: QILU PHARM HAINAN

APPLICATION
ANDA203711
TYPE
ANDA
ORIGINAL APPROVAL
2014-09-08
LATEST ACTION
2025-09-16
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ONDANSETRON HYDROCHLORIDEPrescription
ONDANSETRON HYDROCHLORIDE EQ 2MG BASE/ML · INJECTABLE · INJECTION

Approval history

2025-09-16Labeling · Supplement 17 · standardAP
2022-02-28Labeling · Supplement 13 · standardAP
2021-09-01Labeling · Supplement 2 · standardAP
2021-09-01Labeling · Supplement 10 · standardAP
2015-04-03Labeling · Supplement 1 · standardAP
2014-09-08UNKNOWN · OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →